Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Change in Acquisitions & Divestments (2019 - 2025)

Historic Change in Acquisitions & Divestments for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $240.6 million.

  • Beam Therapeutics' Change in Acquisitions & Divestments rose 3149.95% to $240.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $753.7 million, marking a year-over-year increase of 674.18%. This contributed to the annual value of $680.4 million for FY2024, which is 3757.36% down from last year.
  • Beam Therapeutics' Change in Acquisitions & Divestments amounted to $240.6 million in Q3 2025, which was up 3149.95% from $166.7 million recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Change in Acquisitions & Divestments peaked at $365.5 million during Q2 2023, and registered a low of $20.4 million during Q1 2021.
  • Moreover, its 5-year median value for Change in Acquisitions & Divestments was $217.1 million (2025), whereas its average is $217.3 million.
  • In the last 5 years, Beam Therapeutics' Change in Acquisitions & Divestments skyrocketed by 68391.2% in 2022 and then plummeted by 5696.63% in 2023.
  • Beam Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $106.4 million in 2021, then surged by 238.59% to $360.1 million in 2022, then crashed by 56.97% to $155.0 million in 2023, then fell by 16.59% to $129.2 million in 2024, then soared by 86.18% to $240.6 million in 2025.
  • Its last three reported values are $240.6 million in Q3 2025, $166.7 million for Q2 2025, and $217.1 million during Q1 2025.